Eli Lilly and Company (LLY)
Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline
Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion in cash, part of a deal-making push to broaden its treatments for immune-related and allergic diseases. The acquisition continues a run of dealmaking for Lilly, whose deal spending this year has outpaced prior years as it looks to diversify beyond its blockbuster obesity and diabetes franchises.
LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.
Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock.
Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions.
Eli Lilly to Buy Merida Biosciences For Up to $2.875 Billion
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker's immunology portfolio.
US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
Eli Lilly said on Friday the U.S. FDA has approved its diabetes drug Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.
LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.
Eli Lilly Has a $100 Billion Revenue Story in the Making
Eli Lilly (NYSE:LLY | LLY Price Prediction) is trading at $1,255.40, and management has guided fiscal 2026 revenue between $85 billion and $87 billion.
Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.
The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event of at least one weight-related health condition.
Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk
Eli Lilly has strengthened its global obesity drug market dominance, outpacing Novo Nordisk despite intensifying competition and pricing pressures. LLY's US market share has plateaued at 60–61%, but rising total prescriptions and global expansion underpin continued growth prospects. Valuation has compressed to just over 30x forward earnings, reflecting market expectations for growth deceleration and ongoing pricing competition.
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Stock Forecast: The Market is Sleeping on Eli Lilly's Next $1 Trillion Opportunity
Eli Lilly (NYSE:LLY | LLY Price Prediction) has quietly transformed itself into the first pharmaceutical company ever valued above $1 trillion, and yet the market may still be underpricing what comes next.
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
